Corvus Pharma Com (CRVS) Stock Price, Quote & News

Company Profile

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1b/2 clinical trial for the treatment of peripheral T cell lymphoma, atopic dermatitis, hid...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 900 4520

Website: www.corvuspharma.com

Address:

901 Gateway Boulevard, Third Floor, South San Francisco, United States

tradingjunk321 May. 2 at 1:01 AM

$CRVS This is not me, just how I feel!

1 · Reply

MedicalDoctorInvestor May. 1 at 9:13 PM

$CRVS down 4% on the week. As I predicted

1 · Reply

MedicalDoctorInvestor May. 1 at 8:49 PM

$CRVS

1 · Reply

MedicalDoctorInvestor May. 1 at 8:22 PM

$CRVS hey Jelly!

1 · Reply

MedicalDoctorInvestor May. 1 at 7:27 PM

$CRVS $APGE 🚨Checkout APGE. Positioned to be a big winner in AD!

0 · Reply

tradingjunk321 May. 1 at 2:07 PM

$CRVS I don't know why I didn't buy 500k shares under $1 WTF 😳

1 · Reply

Quantumup May. 1 at 11:58 AM

Rothschild & Co Redburn🏁 $APGE Buy; $140 $CRVS $NKTR SNY - REGN LLY Here's what Rothschild & Co Redburn said in its initiation report: https://x.com/Quantumup1/status/2050182223035334732?s=20

0 · Reply

tradingjunk321 May. 1 at 7:40 AM

$CRVS Going up ⬆️

1 · Reply

lousjamsession May. 1 at 6:23 AM

$CRVS ...

0 · Reply

abc12332 May. 1 at 4:15 AM

$CRVS Personally I bought a little yesterday. smidges don’t have to much impact over when you already have a sizable position like us old timers, but I couldn’t resist. Onward and upward.

1 · Reply

Corvus Pharmaceuticals Appoints Andrew C. Chan, M.D.

Apr 21, 2026, 7:30 AM EDT - 10 days ago

Corvus Pharmaceuticals to Host Investor and Analyst Meeting on May 14, 2026 to Highlight Soquelitinib Data Being Presented at the Society for Investigative Dermatology (SID) Annual Meeting

Mar 12, 2026, 4:30 PM EDT - 7 weeks ago

Corvus Pharmaceuticals Earnings Call Transcript: Q4 2025

Mar 12, 2026, 4:01 PM EDT - 7 weeks ago

Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

Mar 5, 2026, 4:01 PM EST - 2 months ago

Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026

Feb 26, 2026, 2:40 PM EST - 2 months ago

Corvus Pharmaceuticals Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 23, 2026, 4:01 PM EST - 2 months ago

Corvus Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Jan 23, 2026, 5:00 PM EST - 3 months ago

Corvus Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $201M

Jan 21, 2026, 10:53 PM EST - 3 months ago

Corvus Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock

Jan 20, 2026, 4:01 PM EST - 3 months ago

Corvus Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Jan 20, 2026, 2:10 PM EST - 3 months ago

What made Corvus stock double on Tuesday and is it sustainable?

Jan 20, 2026, 2:00 PM EST - 3 months ago

Corvus Stock Spikes On Heels Of Strong Eczema Study Results

Jan 20, 2026, 8:00 AM EST - 3 months ago

Corvus Pharmaceuticals Transcript: Study result

Jan 16, 2026, 4:01 PM EST - 3 months ago

Corvus Pharmaceuticals to Announce Results from Cohort 4 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Nov 10, 2025, 8:30 AM EST - 6 months ago

Corvus Pharmaceuticals Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 4, 2025, 4:30 PM EST - 6 months ago

Corvus Pharmaceuticals Earnings Call Transcript: Q3 2025

Nov 4, 2025, 4:01 PM EST - 6 months ago

Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2025 Financial Results

Oct 31, 2025, 7:30 AM EDT - 6 months ago

Corvus Pharmaceuticals to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference

Oct 28, 2025, 4:01 PM EDT - 6 months ago

Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2025 Financial Results on November 4, 2025

Oct 17, 2025, 10:00 AM EDT - 7 months ago

Corvus Pharmaceuticals Announces Presentation of Interim Data from the Phase 1b/2 Clinical Trial of Ciforadenant for Patients with Metastatic Renal Cell Cancer at the European Society for Medical Oncology (ESMO) Congress 2025

Oct 2, 2025, 4:01 PM EDT - 7 months ago

Corvus Pharmaceuticals Appoints David Moore to Board of Directors

Aug 7, 2025, 4:30 PM EDT - 9 months ago

Corvus Pharmaceuticals Earnings Call Transcript: Q2 2025

Aug 7, 2025, 4:01 PM EDT - 9 months ago

Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2025 Financial Results

Jun 5, 2025, 9:20 AM EDT - 11 months ago

Corvus Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2025

Jun 4, 2025, 7:00 AM EDT - 11 months ago

Corvus Pharmaceuticals Announces Full Data from Cohort 3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

May 28, 2025, 4:01 PM EDT - 1 year ago

Corvus Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference

May 9, 2025, 11:57 AM EDT - 1 year ago

Why Is Corvus Pharmaceuticals Stock Soaring On Friday?

May 8, 2025, 4:30 PM EDT - 1 year ago

Corvus Pharmaceuticals Earnings Call Transcript: Q1 2025

May 8, 2025, 4:02 PM EDT - 1 year ago

Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2025 Financial Results

May 8, 2025, 4:01 PM EDT - 1 year ago

Corvus Pharmaceuticals Announces Data from Cohorts 1-3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Apr 23, 2025, 4:08 PM EDT - 1 year ago

Corvus Pharmaceuticals to Present New Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on May 8, 2025

Apr 9, 2025, 4:01 PM EDT - 1 year ago

Corvus Pharmaceuticals Appoints Richard A. van den Broek to Board of Directors

Mar 27, 2025, 12:00 PM EDT - 1 year ago

Corvus Pharmaceuticals Transcript: H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

Mar 25, 2025, 4:30 PM EDT - 1 year ago

Corvus Pharmaceuticals Earnings Call Transcript: Q4 2024

Mar 25, 2025, 4:01 PM EDT - 1 year ago

Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 20, 2025, 8:00 AM EDT - 1 year ago

Corvus Pharmaceuticals Announces Presentation of Additional Data from the Phase 1/1b Clinical Trial of Soquelitinib for Patients with T Cell Lymphoma

Mar 19, 2025, 4:01 PM EDT - 1 year ago

Corvus Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

Mar 17, 2025, 4:01 PM EDT - 1 year ago

Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025

Mar 12, 2025, 8:00 AM EDT - 1 year ago

Corvus Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial of Soquelitinib for Patients with Autoimmune Lymphoproliferative Syndrome (ALPS)

Feb 11, 2025, 9:20 AM EST - 1 year ago

Corvus Pharmaceuticals Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025

Feb 4, 2025, 8:00 AM EST - 1 year ago

Corvus Pharmaceuticals to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Jan 15, 2025, 2:15 PM EST - 1 year ago

Corvus Pharmaceuticals Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 13, 2025, 7:30 AM EST - 1 year ago

Corvus Pharmaceuticals Announces Data from Cohort 2 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Jan 7, 2025, 4:01 PM EST - 1 year ago

Corvus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 18, 2024, 1:23 PM EST - 1 year ago

Why Is Corvus Pharmaceuticals Stock Trading Lower On Wednesday?

Dec 18, 2024, 8:42 AM EST - 1 year ago

Heico, Corvus Pharmaceuticals, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session

HEI TSLA

Dec 18, 2024, 8:00 AM EST - 1 year ago

Corvus Pharmaceuticals Transcript: Study Update

Dec 18, 2024, 7:30 AM EST - 1 year ago

Corvus Pharmaceuticals Announces Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Dec 17, 2024, 4:01 PM EST - 1 year ago

Corvus Pharmaceuticals to Announce Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on December 18, 2024

Dec 4, 2024, 4:05 PM EST - 1 year ago

Corvus Pharmaceuticals Announces Publication of Biochemistry and Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to Modulate Tumor Immunity

Nov 14, 2024, 10:01 AM EST - 1 year ago

Corvus Pharmaceuticals Announces New Preclinical Data Highlighting Potential of Soquelitinib to Treat Systemic Sclerosis

Nov 12, 2024, 4:30 PM EST - 1 year ago

Corvus Pharmaceuticals Earnings Call Transcript: Q3 2024

Nov 12, 2024, 4:01 PM EST - 1 year ago

Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results

Nov 9, 2024, 1:40 PM EST - 1 year ago

Corvus Pharmaceuticals Announces New Data Highlighting Potential of Ciforadenant to Overcome Immunotherapy Resistance in Metastatic Castration Resistant Prostate Cancer

Nov 5, 2024, 4:02 PM EST - 1 year ago

Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2024 Financial Results on November 12, 2024

Sep 17, 2024, 8:00 AM EDT - 1 year ago

Kaskela Law LLC Announces Shareholder Investigation of Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) and Encourages Investors to Contact the Firm

Sep 10, 2024, 12:00 PM EDT - 1 year ago

Corvus Pharmaceuticals Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

$Corvus Pharmaceuticals Initiates Registrational Phase 3 Clinical Trial of Soquelitinib for Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma$

Sep 10, 2024, 8:30 AM EDT - 1 year ago

Corvus Pharmaceuticals Initiates Registrational Phase 3 Clinical Trial of Soquelitinib for Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma

Sep 3, 2024, 4:05 PM EDT - 1 year ago

Corvus Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 6, 2024, 4:30 PM EDT - 1 year ago

Corvus Pharmaceuticals Earnings Call Transcript: Q2 2024

Aug 6, 2024, 4:01 PM EDT - 1 year ago

Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2024 Financial Results

$Corvus Pharmaceuticals Granted FDA Fast Track Designation for Soquelitinib for Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)$

Aug 1, 2024, 8:30 AM EDT - 1 year ago

Corvus Pharmaceuticals Granted FDA Fast Track Designation for Soquelitinib for Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

Jul 31, 2024, 8:30 AM EDT - 1 year ago

Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2024 Financial Results on August 6, 2024

Jun 5, 2024, 3:00 PM EDT - 2 years ago

Corvus Pharmaceuticals Transcript: Jefferies 2024 Global Healthcare Conference

May 30, 2024, 4:02 PM EDT - 2 years ago

Corvus Pharmaceuticals to Present at the Jefferies Global Health Conference

May 6, 2024, 4:30 PM EDT - 2 years ago

Corvus Pharmaceuticals Earnings Call Transcript: Q1 2024

May 6, 2024, 4:01 PM EDT - 2 years ago

Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results

May 2, 2024, 4:02 PM EDT - 2 years ago

Corvus Pharmaceuticals to Provide Business Update and First Quarter 2024 Financial Results on May 6, 2024

Mar 19, 2024, 4:30 PM EDT - 2 years ago

Corvus Pharmaceuticals Earnings Call Transcript: Q4 2023

Nov 7, 2023, 4:30 PM EST - 2 years ago

Corvus Pharmaceuticals Earnings Call Transcript: Q3 2023

Sep 7, 2023, 8:30 AM EDT - 2 years ago

Corvus Pharmaceuticals Transcript: Status Update

Aug 8, 2023, 4:30 PM EDT - 2 years ago

Corvus Pharmaceuticals Earnings Call Transcript: Q2 2023

Jun 15, 2023, 4:00 PM EDT - 3 years ago

Corvus Pharmaceuticals Transcript: AGM 2023

May 8, 2023, 4:30 PM EDT - 3 years ago

Corvus Pharmaceuticals Earnings Call Transcript: Q1 2023

Mar 28, 2023, 4:30 PM EDT - 3 years ago

Corvus Pharmaceuticals Earnings Call Transcript: Q4 2022

Dec 12, 2022, 4:30 PM EST - 3 years ago

Corvus Pharmaceuticals Transcript: Status Update

Nov 3, 2022, 6:27 AM EDT - 3 years ago

Corvus Pharmaceuticals Earnings Call Transcript: Q3 2022

Aug 8, 2022, 4:30 PM EDT - 4 years ago

Corvus Pharmaceuticals Earnings Call Transcript: Q2 2022

May 10, 2022, 9:00 AM EDT - 4 years ago

Corvus Pharmaceuticals Transcript: Study Update

Mar 10, 2022, 4:30 PM EST - 4 years ago

Corvus Pharmaceuticals Earnings Call Transcript: Q4 2021

Nov 12, 2021, 9:00 AM EST - 4 years ago

Corvus Pharmaceuticals Transcript: Status Update

Jun 15, 2021, 4:00 PM EDT - 5 years ago

Corvus Pharmaceuticals Transcript: AGM 2021

Feb 4, 2021, 8:30 AM EST - 5 years ago

Corvus Pharmaceuticals Transcript: Study Update

Nov 12, 2020, 11:00 AM EST - 5 years ago

Corvus Pharmaceuticals Transcript: Status Update

Jul 30, 2020, 4:30 PM EDT - 6 years ago

Corvus Pharmaceuticals Earnings Call Transcript: Q2 2020

Jul 7, 2020, 8:30 AM EDT - 6 years ago

Corvus Pharmaceuticals Transcript: Study Update

Jun 9, 2020, 4:00 PM EDT - 6 years ago

Corvus Pharmaceuticals Transcript: AGM 2020

Apr 30, 2020, 4:30 PM EDT - 6 years ago

Corvus Pharmaceuticals Earnings Call Transcript: Q1 2020

Mar 5, 2020, 4:30 PM EST - 6 years ago

Corvus Pharmaceuticals Earnings Call Transcript: Q4 2019

Nov 8, 2019, 6:00 PM EST - 7 years ago

Corvus Pharmaceuticals Transcript: Status Update

Oct 29, 2019, 4:30 PM EDT - 7 years ago

Corvus Pharmaceuticals Earnings Call Transcript: Q3 2019

Aug 1, 2019, 4:30 PM EDT - 7 years ago

Corvus Pharmaceuticals Earnings Call Transcript: Q2 2019

Jun 2, 2019, 7:00 PM EDT - 7 years ago

Corvus Pharmaceuticals Transcript: Status Update

May 9, 2019, 4:30 PM EDT - 7 years ago

Corvus Pharmaceuticals Earnings Call Transcript: Q1 2019

tradingjunk321 May. 2 at 1:01 AM

$CRVS This is not me, just how I feel!

1 · Reply

MedicalDoctorInvestor May. 1 at 9:13 PM

$CRVS down 4% on the week. As I predicted

1 · Reply

MedicalDoctorInvestor May. 1 at 8:49 PM

$CRVS

1 · Reply

MedicalDoctorInvestor May. 1 at 8:22 PM

$CRVS hey Jelly!

1 · Reply

MedicalDoctorInvestor May. 1 at 7:27 PM

$CRVS $APGE 🚨Checkout APGE. Positioned to be a big winner in AD!

0 · Reply

tradingjunk321 May. 1 at 2:07 PM

$CRVS I don't know why I didn't buy 500k shares under $1 WTF 😳

1 · Reply

Quantumup May. 1 at 11:58 AM

Rothschild & Co Redburn🏁 $APGE Buy; $140 $CRVS $NKTR SNY - REGN LLY Here's what Rothschild & Co Redburn said in its initiation report: https://x.com/Quantumup1/status/2050182223035334732?s=20

0 · Reply

tradingjunk321 May. 1 at 7:40 AM

$CRVS Going up ⬆️

1 · Reply

lousjamsession May. 1 at 6:23 AM

$CRVS ...

0 · Reply

abc12332 May. 1 at 4:15 AM

$CRVS Personally I bought a little yesterday. smidges don’t have to much impact over when you already have a sizable position like us old timers, but I couldn’t resist. Onward and upward.

1 · Reply

ripster47 Apr. 30 at 9:20 PM

$XBI ❤️ Finally getting some love $XBI $CRVS $CTMX $TMDX $MEDP , 1 DAY of green after so much pain last few sessions Just need Yields to stay down and back up we go A Peace deal should help @Pharmdca @PharmDabbler @semodough @LTbioinvestor

0 · Reply

KingKai2020 Apr. 30 at 7:45 PM

$CRVS OT....another win for the good guys on $AXSM. If anyone cares.. $BHVN been beaten down on lots of bad news the last 12-18 months, but I think the risk/reward is compeling at burrent levels. P.S.wish that I got more $CRVS yest!!

1 · Reply

Jellysquid1 Apr. 30 at 7:19 PM

$CRVS Med Dic At work…. 🤣🤣🤣🤣

1 · Reply

MedicalDoctorInvestor Apr. 30 at 7:13 PM

$CRVS

0 · Reply

MedicalDoctorInvestor Apr. 30 at 6:58 PM

$CRVS here we go it’s turning. Ready for the red

0 · Reply

Jellysquid1 Apr. 30 at 6:12 PM

$CRVS A GREAT PAIR ! Soquelitinib could be The Next Big Blockbuster!

2 · Reply

tradingjunk321 Apr. 30 at 4:50 PM

$CRVS Best post I've seen and exciting! This is best in class and I strongly feel this will be acquired between now and end of 2027! Bidding war, read the posts below!

1 · Reply

MedicalDoctorInvestor Apr. 30 at 3:48 PM

$CRVS trading junkies

1 · Reply

MedicalDoctorInvestor Apr. 30 at 1:53 PM

$CRVS the gamblers choice

1 · Reply

MedicalDoctorInvestor Apr. 30 at 1:52 PM

$CRVS this trash is up 9 cents when the market is boldly green. 😆 what a piece of trash. Trash trash trash. Will be red by close

1 · Reply

tradingjunk321 Apr. 30 at 12:51 PM

$CRVS Moore!

1 · Reply

tradingjunk321 Apr. 30 at 12:12 PM

$CRVS Exciting next 14 months with a few readouts!

0 · Reply

Market Cap	1.28B
Revenue (ttm)	0.00
Net Income (ttm)	-15.28M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	862,000
Avg Vol	1,266,290
Day's Range	N/A - N/A
Shares Out	84.09M
Stochastic %K	24%
Beta	0.97
Analysts	Strong Sell
Price Target	$33.33